Nine new com­pa­nies have an­nounced vol­un­tary drug pric­ing deals with the White House, look­ing to avoid in­dus­try tar­iffs and in­clu­sion in two CMS pi­lot pro­grams...

End­points is field­ing the next Bio­phar­ma Sen­ti­ment In­dex (BP­SI) — a con­cise, three-minute sur­vey that dis­tills thou­sands of in­dus­try views in­to a clear quar­ter­ly bench­mark...

The FDA ap­proved rus­fer­tide, a new drug from Take­da and Pro­tag­o­nist Ther­a­peu­tics to treat a rare blood dis­ease.

Rus­fer­tide, which will be brand­ed as Mim­ry­lo, can...

Eli Lil­ly is fur­ther strength­en­ing its po­si­tion in im­munol­o­gy with its 13th ac­qui­si­tion of the year, pay­ing up to $2.875 bil­lion for Meri­da Bio­sciencesand...

MU­NICH — Ar­row­head is on course to crash Io­n­is Phar­ma­ceu­ti­cals’ par­ty.

Ar­row­head’s RNA in­ter­fer­ence drug Re­dem­p­lo looked safer as well as ef­fec­tive in two late-stage...

MU­NICH— As­traZeneca’s oral re­lax­in ag­o­nist was able to im­prove car­diac func­tion in some, though not all, pa­tients in a mid-stage tri­al. While the study...